Subcutaneous epcoritamab in combination with r (2) (Rituximab and Lenalidomide) in patients with relapsed or refractory follicular lymphoma: preliminary results from a Phase 1/2 Trial
Authors
Linton, Kim MWahlin, B.
Leepa, S.
Morschhauser, F.
Elliot, B.
Liu, T.
Stirner, M. C.
Abbas, A.
Falchi, L.
Affiliation
The Christie NHS Foundation Trust and Manchester Cancer Research Centre, ManchesterIssue Date
2021
Metadata
Show full item recordCitation
Linton KM, Wahlin B, Leepa S, Morschhauser F, Elliot B, Liu T, et al. Subcutaneous Epcoritamab in Combination with R (2) (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413906102.Journal
BloodDOI
10.1182/blood-2021-146629Additional Links
https://dx.doi.org/10.1182/blood-2021-146629Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-146629